文献速递银屑病与炎症性皮肤病

生物制剂治疗儿童斑块状银屑病的系统评价与网状Meta分析

Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta-analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-10-15

该系统评价与网状Meta分析纳入7项RCT共1016例儿童斑块状银屑病患者,比较生物制剂疗效与安全性。所有生物制剂在PASI75和PASI90应答上均显著优于安慰剂,但各生物制剂间无显著差异。Ixekizumab在PASI100应答排名最高,Secukinumab高剂量在PASI90排名最佳,Ustekinumab标准剂量在CDLQI 0/1和PASI75排名最优。

要点

  • 所有生物制剂在PASI75和PASI90应答上均显著优于安慰剂。
  • 各生物制剂之间疗效无显著差异,排名趋势因结局指标而异。
  • 仍需更大样本试验确定儿童斑块状银屑病最佳治疗选择。

核心结论

  • 所有生物制剂(不包括非生物制剂对照甲氨蝶呤和FAEs)在治疗中重度儿童斑块状银屑病上均显著优于安慰剂。
  • 各生物制剂之间无显著差异,Ixekizumab和Secukinumab在PASI90应答上呈较高趋势,Ustekinumab在CDLQI和PASI75应答上呈较高趋势。

研究设计与样本

  • 系统评价与网状Meta分析,检索PubMed、Embase、Cochrane CENTRAL和clinicaltrials.gov的随机对照试验。
  • 采用固定效应频率学网状Meta分析,计算SUCRA和平均排名。
  • 纳入7项RCT共1016例银屑病患者。

主要发现

  • 与安慰剂相比,所有生物制剂均显著提高PASI75和PASI90应答。
  • Ixekizumab在PASI100应答的SUCRA最高(SUCRA: 0.9,Mean Rank: 1.8)。
  • Secukinumab高剂量在PASI90应答的SUCRA最高(SUCRA: 0.8,Mean Rank: 3.0)。
  • Ustekinumab标准剂量在CDLQI 0/1(SUCRA: 0.8,Mean Rank: 2.2)和PASI75(SUCRA: 0.9,Mean Rank: 2.2)应答中表现最优。

关键数值与推荐

  • 主要结局包括第12-16周PASI75、PASI90、PASI100、CDLQI 0/1以及第12-20周安全性结局。
  • 计算应答点概率并以每1000例患者相对安慰剂的绝对风险差异(95%CI)表示。

临床怎么用

  • 生物制剂均可显著改善儿童中重度斑块状银屑病的PASI75和PASI90应答。
  • 选择生物制剂时需综合考虑PASI100、PASI90、PASI75及CDLQI等不同结局的排名趋势。

局限性

  • 各生物制剂间无显著差异,需更大样本试验确定最佳治疗模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: As biologic therapy is increasingly being utilized in the treatment of paediatric psoriasis, we aim to perform a systematic review and network meta-analysis to compare the efficacy and safety of available biologic treatments for moderate to severe paediatric plaque psoriasis. METHODS: Relevant randomized controlled trials (RCTs) were searched for in PubMed, Embase, Cochrane CENTRAL and clinicaltrials.gov. We performed a fixed-effects frequentist network meta-analysis (NMA) with the surface under the cumulative ranking curve (SUCRA) calculated for and mean ranking calculated. The main outcomes of interest were a ≥75% improvement in PASI score (PASI75), ≥90% improvement in PASI score (PASI90), 100% improvement in PASI score (PASI100), CDLQI score of 0/1 (CDLQI 0/1) at weeks 12-16 and safety outcomes at 12-20 weeks. Point probabilities of response were also calculated, presented as absolute risk differences per 1000 patients with their 95% CIs compared to placebo. RESULTS: Seven RCTs comprising 1016 psoriasis patients were included. Compared to placebo, all biologic therapies exhibited a significantly higher PASI90 and PASI75 response. Based on the SUCRA, Ixekizumab ranked highest in achieving the PASI100 (SUCRA: 0.9, Mean Rank: 1.8) response. Secukinumab high dose ranked the best for PASI90 (SUCRA: 0.8, Mean Rank: 3.0). For the CDLQI 0/1 (SUCRA: 0.8, Mean Rank: 2.2) response and the PASI75 (SUCRA: 0.9, Mean Rank: 2.2) response, standard dose Ustekinumab exhibited superior performance. CONCLUSIONS: All biologic agents (not including non-biologic comparators methotrexate and FAEs) were significantly superior to placebo, with no significant difference between individual biologic therapies, for the treatment of moderate-to-severe paediatric plaque psoriasis. Ixekizumab and Secukinumab demonstrated a trend towards a higher PASI90 response, while Ustekinumab showed a trend towards increased CDLQI and PASI75 responses. These findings highlight the need for better-powered trials in this population to determine the optimal treatment modality. PROSPERO NUMBER: CRD42023476983.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Aljalfan AA, Maniya MT, Sachedina D, et al. Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta-analysis. J Eur Acad Dermatol Venereol. 2025. PMID: 41090545. doi:10.1111/jdv.70084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。